Gene therapy shot aims to slow vision loss in rare eye disease
NCT ID NCT07311863
First seen Jan 09, 2026 · Last updated May 14, 2026 · Updated 22 times
Summary
This early-stage study tests a single injection of a gene therapy called UGX202 in 6 adults with advanced retinitis pigmentosa, a genetic eye disease that causes vision loss. The main goal is to check if the treatment is safe and tolerable over 52 weeks. Researchers will also look for early signs that it might help preserve or improve eyesight.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA (RP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Eye & ENT Hospital of Fudan University
Shanghai, Shanghai Municipality, 200031, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.